Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Alternative Names: [14C]-LX4211; LP-802034; LX-4211; SAR 439954

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Glycosides; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2017 Sanofi plans a phase III trial for Type-2 diabetes mellitus (Adjunctive therapy) in December 2017 (NCT03332771)
  • 26 Oct 2017 Sanofi plans the phase III SCORED trial to evaluate the effect of Sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes (NCT03315143)
  • 25 Oct 2017 Sanofi initiates enrolment in the SOTA-GLIM trial for Type-2 diabetes mellitus (Adjunctive therapy) in USA (PO) (NCT03332771)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top